Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Several Ludwig Oxford researchers present at the American Association for Cancer Research (AACR) Annual Meeting.

The AACR Annual Meeting is one of the largest events in the cancer conference calendar and draws global audiences of scientists, clinicians, other health care professionals, survivors, patients, and advocates.

Ludwig Oxford’s cancer research is represented by eight presenters at this year’s meeting.


  • Professor Yang Shi presents “Epigenetic regulation in immuno-oncology” in the session on Epigenetics, Chromatin Architecture, and Gene Regulation: Mechanisms and Therapeutic Opportunities in Cancer (Major symposium)
  • Dr Véronique Lafleur (Ratcliffe group) presents “Bi-directional crosstalk between the HIF and AHR transcription factors in clear cell kidney cancer” in the session on Transcription Factors in Cancer (Mini symposium)


  • Dr Thomas Carroll (Lu lab): “Comprehensive molecular profiling to predict first-line immunochemotherapy outcomes in inoperable esophageal adenocarcinoma”
  • Jessica Kindrick (Ratcliffe and Mole labs): “Correlating locus-specific changes in histone trimethylation and gene expression in hypoxia”
  • Samvid Kurlekar (Ratcliffe lab): “Negative cellular outcomes following acute in vivo Vhl inactivation in mice”
  • Dr Joanna Lima (Ratcliffe lab): “A novel lineage-tracing model of Vhl deletion reveals time-dependent cellular changes in the kidney”
  • Dr Olivia Lombardi (Ratcliffe and Mole labs): “Multi region single cell sequencing reveals dedifferentiation programs, angiogenic heterogeneity and the effect of microenvironmental hypoxia in ccRCC tumors”
  • Professor David Mole: “Pan-cancer analysis of HIF pathways defines a robust molecular signature that reflects tissue and cellular hypoxia in bulk and single-cell RNA-seq analyses”